Clinical Trials on Baetz-Greenwalt Syndrome in Luxembourg

Total 14 results

Luxembourg Institute of Health
ViewMind

Recruiting

Digital Cognition Study During Long-COVID (DIGICOG)

COVID-19, Long Haul

Luxembourg
CytoSorbents Europe GmbH

Terminated

Ticagrelor Removal Study Using CytoSorb® 300 mL Device During CPB in Patients Undergoing Emergent Cardiothoracic Surgery (CyTation)

Acute Coronary Syndrome

Germany, Luxembourg
UMC Utrecht

Unknown

Randomized "All-comer" Evaluation of a Permanent Polymer Resolute Integrity Stent Versus a Polymer Free Cre8 Stent

Acute Coronary Syndrome | Stable Angina Pectoris

Netherlands, Luxembourg
Celgene

Completed

Non-interventional Study of Lenalidomide in the Clinical Routine Treatment of TD Patients With IPSS Low or Int-1 MDS and Isolated Del(5q) (PASS MDS del5q)

Myelodysplastic Syndrome

Spain, United Kingdom, Denmark, Germany, France, Greece, Italy, Sweden, Belgium, United States, Luxembourg, Norway
Stichting Hemato-Oncologie voor Volwassenen Nederland
Deutsch-Österreichische Studiengruppe Akute Myeloische Leukämie (AMLSG)

Recruiting

A Study of Ivosidenib or Enasidenib in Combination With Induction Therapy and Consolidation Therapy, Followed by Maintenance Therapy in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myedysplastic Syndrome EB2, With an IDH1 or IDH2 Mutation, Respectively, Eligible for Intensive Chemotherapy (HOVON150AML)

Acute Myeloid Leukemia | Myelodysplastic Syndrome With Excess Blasts-2

Australia, Austria, Belgium, Estonia, Finland, France, Germany, Ireland, Lithuania, Luxembourg, Netherlands, Norway, Spain, Sweden, Switzerland
Stichting Hemato-Oncologie voor Volwassenen Nederland
Astellas Pharma Global Development, Inc.; Deutsch-Österreichische Studiengruppe...

Active, not recruiting

A Study of Gilteritinib Versus Midostaurin in Combination With Induction and Consolidation Therapy Followed by One-year Maintenance in Patients With Newly Diagnosed Acute Myeloid Leukemia or Myelodysplastic Syndromes With Excess Blasts-2 With FLT3 Mutations Eligible for Intensive Chemotherapy (HOVON 156 AML)

Acute Myeloid Leukemia | Myelodysplastic Syndrome With Excess Blasts-2

Netherlands, Belgium, Germany, Switzerland, Australia, Finland, Norway, Sweden, Austria, France, Ireland, Lithuania, Luxembourg, Spain
Novo Nordisk A/S

Completed

Observational Prospective Study on Patients Treated With Norditropin®

Chronic Kidney Disease | Turner Syndrome | Noonan Syndrome | Chronic Renal Insufficiency | Growth Hormone Disorder | Growth Hormone Deficiency in Children | Adult Growth Hormone Deficiency | Genetic Disorder | Foetal Growth Problem | Small for Gestational Age

Israel, Saudi Arabia, Spain, Argentina, Russian Federation, Germany, Netherlands, Italy, Belgium, United Kingdom, Slovenia, Ireland, Sweden, Denmark, Hungary, Finland, Norway, France, Czechia, Lithuania, Luxembourg, Serbia, Switzerland
GlaxoSmithKline

Completed

KALETRA Or LEXIVA With Ritonavir Combined With EPIVIR And Abacavir In Naive Subjects Over 48 Weeks

HIV Infection | Infection, Human Immunodeficiency Virus

United States, Belgium, France, Germany, Spain, Canada, Italy, Portugal, Romania, Austria, Switzerland, Poland, Latvia, Luxembourg
University of Minnesota
National Health and Medical Research Council, Australia; Bristol-Myers Squibb; National Institutes of Health Clinical Center (CC) and other collaborators

Completed

Strategic Timing of Antiretroviral Treatment (START)

HIV Infection

Spain, United States, United Kingdom, Ireland, Australia, Argentina, Denmark, Sweden, Israel, Switzerland, Germany, Brazil, Norway, Chile, Thailand, Peru, Portugal, Greece, Luxembourg, Uganda, Austria, Belgium, Czechia, Estonia, Finland, ... and more
AstraZeneca

Completed

Study Evaluating How Patients With Acute Coronary Syndrome Are Managed During 2 Years After Discharge (EPICOR)

Myocardial Infarction | Coronary Artery Disease | Acute Coronary Syndrome | Unstable Angina | ACS

Brazil, France, Italy, Mexico, Spain, Turkey, United Kingdom, Germany, Poland, Romania, Denmark, Finland, Norway, Argentina, Belgium, Netherlands, Greece, Luxembourg, Slovenia, Venezuela
Boehringer Ingelheim

Completed

Tipranavir/Ritonavir vs. Genotypically Defined Protease Inhibitor/Ritonavir in HIV Patients (RESIST-2)

HIV Infections

Argentina, Austria, Belgium, Brazil, Denmark, France, Germany, Greece, Ireland, Italy, Mexico, Netherlands, Portugal, Spain, Sweden, Switzerland, United Kingdom
National Institute of Allergy and Infectious Diseases...

Completed

A Comparison of Two Ways to Manage Anti-HIV Treatment (The SMART Study)

HIV Infections

United Kingdom, Argentina, Switzerland, France, Brazil, United States, Estonia, Spain, Australia, Peru, Austria, Belgium, Canada, Germany, Ireland, Israel, Italy, Japan, Lithuania, Luxembourg, Martinique, New Zealand, Norway, Poland, Puerto... and more
Boehringer Ingelheim

Completed

Rollover Trial Safety and Tolerability of Combination Tipranavir and Ritonavir Use in HIV 1 Infected Subjects

HIV Infections

United States, Argentina, Australia, Austria, Belgium, Brazil, Canada, Denmark, France, Germany, Greece, Italy, Mexico, Netherlands, Portugal, Spain, Switzerland, United Kingdom
Tibotec Pharmaceuticals, Ireland

Approved for marketing

TMC114-C226: An Early Access Program to Evaluate the Long-term Safety and Tolerability of TMC114 Combined With a Low Dose of Ritonavir (TMC114/r) With Other Antiretrovirals, for HIV-1 Infected Patients Who Have Failed Multiple Antiretroviral Regimens.

HIV Infections

United States, Belgium, Germany, Taiwan, Spain, Switzerland, Mexico, Slovenia, Malaysia, Turkey, Canada, Netherlands, Denmark, Greece, Sweden, Russian Federation, Czech Republic, Puerto Rico, Thailand, Hungary, Luxembourg, Venezuela

Clinical Trials on Baetz-Greenwalt Syndrome in Luxembourg

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Belgium

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations